A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
Phase of Trial: Phase I/II
Latest Information Update: 03 Jul 2015
At a glance
- Drugs Mocetinostat (Primary) ; Gemcitabine
- Indications Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Biomarker
- Sponsors MethylGene
- 12 May 2009 Additional lead trial investigator Martell R identified as reported by ClinicalTrials.gov.
- 16 Dec 2008 Status changed from suspended to completed as reported by Clinicaltrials.gov
- 22 Sep 2008 Planned end date changed from 1 Dec 2008 to 1 Dec 2009, as reported by ClinicalTrials.gov.